For the year ending 2025-12-31, ASRT had -$40,359K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -30,375 |
| Depreciation and amortization | 30,005 |
| Amortization of debt issuance costs | 475 |
| Accretion of interest income from short-term investments | -93 |
| Impairment of intangible assets | 1,700 |
| Loss on assertio therapeutics divestiture | -8,174 |
| Recurring fair value measurements of assets and liabilities | 435 |
| Payment of contingent consideration | 450 |
| Stock-based compensation | 3,454 |
| Provisions for inventory | 4,510 |
| Accounts receivable | 65,990 |
| Inventories | -9,678 |
| Prepaid and other assets | -1,209 |
| Accounts payable and other accrued liabilities | -13,292 |
| Accrued rebates, returns and discounts | 23,062 |
| Net cash (used in) provided by operating activities | -28,182 |
| Assertio therapeutics divestiture | 8,174 |
| Proceeds from maturities of short-term investments | 115,383 |
| Purchases of short-term investments | 119,197 |
| Net cash used in investing activities | -11,988 |
| Payments related to the vesting and settlement of equity awards, net | 189 |
| Net cash used in financing activities | -189 |
| Net decrease in cash and cash equivalents | -40,359 |
| Cash and cash equivalents at beginning of year | 50,588 |
| Cash and cash equivalents at end of year | 10,229 |
Assertio Holdings, Inc. (ASRT)
Assertio Holdings, Inc. (ASRT)